Globally there has been an increase in interest, and research into, the use of controlled substances in the treatment of medical conditions. This has led some jurisdictions to decriminalise or even legalise the use of previously prohibited drugs. However in many jurisdictions a restrictive approach to drug manufacturing and sale prevails.
Gustaf Duhs, Head of Regulatory and a member of Stevens & Bolton’s life sciences team recently participated in a survey on the law related to medicinal use of psychedelics across key European jurisdictions. This was carried out in collaboration with lawyers in life sciences practices at a number of the EU’s leading independent law firms, and the results can be viewed by clicking the button below.